オプションチェーンは、NewAmsterdam Pharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、NewAmsterdam Pharmaの市場センチメントを評価します。.

NewAmsterdam Pharma (NASDAQ:NAMS) 株価情報, オプションチェーン

NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Company N.V. - Warrant

NamSys Inc

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.11 by 45.45 percent. This is a 20 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $118.600 million which beat the analyst consensus estimate of $116.765 million by 1.57 percent. This is a 20.78 percent increase over sales of $98.199 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

VCYT

Veracyte Q4 2024 Adj. EPS $0.06 Misses $0.11 Estimate, Sales $118.600M Beat $116.765M Estimate

Clean Energy Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $109.326 which missed the analyst consensus estimate of $102.618 million by 100.00 percent. This is a 100.00 percent decrease over sales of $106.857 million the same period last year.

CLNE

Clean Energy Fuels Q4 2024 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $109.326 Miss $102.618M Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $210.60 million which missed the analyst consensus estimate of $211.62 million by 0.48 percent. This is a 7.12 percent increase over sales of $196.60 million the same period last year.

MYGN

Myriad Genetics Q4 Adj $0.03, Inline, Sales $210.60M Miss $211.62M Estimate

Guidance

Public Storage Sees FY25 Core FFO Growth (1.9)%-$2.0%; Revenue Growth (1.3)%-0.8%

Earnings Guidance Summarized below are approximate estimates of the key components of our 2025 earnings guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Net income per share (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.52 - $1.58</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Real estate depreciation per share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.68</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other adjustments per share (2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$0.02</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AFFO per share (3)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4.22 - $4.28</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Same store rent growth&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Approx 1.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Occupancy</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Over 98%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash G&amp;A expenses (% of revenues) (4)(5)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Approx 3.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Property expenses (non-reimbursable) (% of revenues) (4)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1.4% - 1.7%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Income tax expenses</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$80 - $90 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Investment volume</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Approx $4.0 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="4" rowspan="1">(1) Net income per share excludes impairments and future foreign currency or derivative gains or losses due to the inherent unpredictability of forecasting&nbsp;these items.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">(2) Includes gain on sales of properties and merger, transaction, and other costs, net.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">(3) AFFO per share excludes merger, transaction, and other costs, net.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">(4) Revenue excludes contractually obligated reimbursements by our clients. Cash G&amp;A expenses exclude stock-based compensation expense.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">(5) G&amp;A expenses inclusive of stock-based compensation expense as a percentage of rental revenue, excluding reimbursements, is expected to be approximately 3.4% - 3.7% in 2025.</td>
</tr>
</tbody>
</table>
</figure>

Realty Income Sees FY25 Net Income $1.52-$1.58; AFFO $4.22-$4.28; ~1% Same Store Rent Growth

Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.05 by 80 percent. The company reported quarterly sales of $167.63 million which beat the analyst consensus estimate of $160.37 million by 4.53 percent. This is a 14.36 percent decrease over sales of $195.75 million the same period last year.

TREX

Trex Co Q4 2024 GAAP EPS $0.09 Beats $0.05 Estimate, Sales $167.63M Beat $160.37M Estimate

Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) reported quarterly earnings of $2.04 per share which beat the analyst consensus estimate of $0.45 by 353.33 percent. This is a 204.48 percent increase over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $210.067 million which missed the analyst consensus estimate of $222.699 million by 5.67 percent. This is a 2.62 percent increase over sales of $204.712 million the same period last year.

VNOM

Viper Energy Q4 2024 Adj. EPS $2.04 Beats $0.45 Estimate, Sales $210.067M Miss $222.699M Estimate

Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) reported quarterly earnings of $4.21 per share which missed the analyst consensus estimate of $4.24 by 0.71 percent. This is a 0.24 percent increase over earnings of $4.20 per share from the same period last year. The company reported quarterly sales of $1.100 which missed the analyst consensus estimate of $1.174 billion by 100.00 percent. This is a 100.00 percent decrease over sales of $1.093 billion the same period last year.

Public Storage Q4 2024 FFO $4.21 Misses $4.24 Estimate, Sales $1.100 Miss $1.174B Estimate

Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) reported quarterly earnings of $1.05 per share which missed the analyst consensus estimate of $1.07 by 1.87 percent. This is a 3.96 percent increase over earnings of $1.01 per share from the same period last year. The company reported quarterly sales of $1.34 billion which beat the analyst consensus estimate of $1.29 billion by 3.53 percent. This is a 24.56 percent increase over sales of $1.08 billion the same period last year.

Realty Income Q4 FFO $1.05 Misses $1.07 Estimate, Sales $1.34B Beat $1.29B Estimate

Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) sees Q1 sales of $13.000 million-$15.000 million vs $15.75 million analyst estimate.

NVTS

Navitas Semiconductor Sees Q1 Sales $13.000M-$15.000M vs $15.75M Est

Management

JACK

Jack in the Box Appoints Lance Tucker As Interim Principal Executive Officer; Succeeds CEO Darin Harris

Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $17.98 million which missed the analyst consensus estimate of $19.02 million by 5.50 percent. This is a 31.01 percent decrease over sales of $26.06 million the same period last year.

Navitas Semiconductor Q4 Adj $(0.06), Inline, Sales $17.98M Miss $19.02M Estimate

Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) reported quarterly sales of $3.71 billion which beat the analyst consensus estimate of $3.53 billion by 5.18 percent. This is a 66.56 percent increase over sales of $2.23 billion the same period last year.

FANG

Diamondback Energy Q4 Sales $3.71B Beat $3.53B Estimate

Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. The company reported quarterly sales of $200.68 million which missed the analyst consensus estimate of $203.12 million by 1.20 percent.

Tempus AI Q4 2024 Adj EPS $(0.18) Beats $(0.20) Estimate, Sales $200.68M Miss $203.12M Estimate

2025 Outlook Our guidance for the full year 2025 is as follows:
<ul>
<li>Total written premiums placed are expected to be between $4.65&nbsp;billion and $4.88&nbsp;billion representing 22% organic growth on the low end of the range, and 28% organic growth on the high end of the range.</li>
<li>Total revenues are expected to be between $350&nbsp;million and $385&nbsp;million representing 11% organic growth on the low end of the range and 22% organic growth on the high end of the range.</li>
</ul>

GSHD

Goosehead Insurance Sees FY25 Total Net Written Premiums $4.65B-$4.88B; Revenues Between $350M-$385M Vs $373.787M Est.

SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) reported quarterly earnings of $1.61 per share which missed the analyst consensus estimate of $2.09 by 22.97 percent. This is a 59.41 percent increase over earnings of $1.01 per share from the same period last year. The company reported quarterly sales of $693.70 million which beat the analyst consensus estimate of $682.03 million by 1.71 percent. This is a 2.77 percent increase over sales of $675.02 million the same period last year.

SBAC

SBA Comms Q4 2024 GAAP EPS $1.61 Misses $2.09 Estimate, Sales $693.70M Beat $682.03M Estimate

KBR Sees FY25 Adj. EPS $3.71-$3.95 Vs $3.86 Est.; Revenue $8.7B-$9.1B Vs 8.913B Est

Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.40 by 97.5 percent. This is a 182.14 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $93.92 million which beat the analyst consensus estimate of $78.57 million by 19.54 percent. This is a 49.05 percent increase over sales of $63.01 million the same period last year.

Goosehead Insurance Q4 Adj $0.79 Beats $0.40 Estimate, Sales $93.92M Beat $78.57M Estimate

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.82 by 10.98 percent. This is a 31.88 percent increase over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $2.122 billion which beat the analyst consensus estimate of $1.999 billion by 6.16 percent. This is a 22.66 percent increase over sales of $1.730 billion the same period last year.

KBR Q4 2024 Adj. EPS $0.91 Beats $0.82 Estimate, Sales $2.122B Beat $1.999B Estimate

Savers Value Village (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.75, a high estimate of $13.00, and a low estimate of $9.00. This current average has decreased by 4.44% from the previous average price target of $11.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1740430870_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Savers Value Village by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Savers Value Village. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Savers Value Village compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Savers Value Village's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Savers Value Village's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SVV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Savers Value Village analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Savers Value Village</h2>
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books and other goods from its non-profit partners ("NPPs"), either directly from them or via on-site donations ("OSDs") at Community Donation Centers at its stores. The company then process, selects, price, merchandise and sell these items in its stores.
<h3>Understanding the Numbers: Savers Value Village's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Savers Value Village displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 1.82%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Savers Value Village's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -0.47%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Savers Value Village's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.44%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Savers Value Village's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Savers Value Village's debt-to-equity ratio stands notably higher than the industry average, reaching 3.09. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Savers Value Village: 4 Analysts Share Their Views

Press Releases

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Legal

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Financing

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

Comments

NewAmsterdam Pharma

NewAmsterdam Pharma (NAMS) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル